Kidney cancer, version 3.2015.

Authors :: Motzer RJ
Jonasch E
Agarwal N
Beard C
Bhayani S
Bolger GB
Chang SS
Choueiri TK
Costello BA
Derweesh IH
Gupta S
Hancock SL
Kim JJ
Kuzel TM
Lam ET
Lau C
Levine EG
Lin DW
Michaelson MD
Olencki T
Pili R
Plimack ER
Rampersaud EN
Redman BG
Ryan CJ
Sheinfeld J
Shuch B
Sircar K
Somer B
Wilder RB
Dwyer M
Kumar R
Source :: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2015 Feb; Vol. 13 (2), pp. 151-9.
Publication Year :: 2015
Abstract: The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.<br /> (Copyright © 2015 by the National Comprehensive Cancer Network.)